By PPN News Staff
The FDA issued an emergency use authorization (EUA) for a new protein-based COVID-19 vaccine made by Novavax Inc. to prevent COVID-19 in people who are 18 years of age and older.
“Patients and providers in the U.S. now have access to a protein-based COVID-19 vaccine backed by data that have demonstrated efficacy, safety and tolerability,” said Karen Kotloff, MD, a professor of pediatrics, at the University of Maryland School of Medicine, in Baltimore, the associate